GLP-1 on the Brain?

GLP-1 is well-known for its gut effects, such as slowing gastric emptying and reducing hunger, which promotes weight loss. However, GLP-1 is also produced in the brain and plays a crucial role in neuroprotection by activating GLP-1 receptor pathways.

This enhances learning and memory in the hippocampus, promotes neurogenesis (brain cell building), reduces inflammation and apoptosis (brain cell death), modulates reward behavior (reduces cravings), and decreases food intake.

Conversely, obesity has been shown to accelerate dementia and cognitive decline, especially in mid-life. This raises the question of whether the inflammation caused by weight-related diseases (like obesity) perpetuates poor eating habits due to a decline in executive brain functioning.

Interestingly, studies have not shown that simply losing weight will improve brain health in patients with diabetes.

So, what can we do? How can we use this information to improve longevity?

Could GLP-1 RAs or GIP/GLP-1 RAs like semaglutide or tirzepatide activate the GLP-1 pathway, induce fat loss, and prevent the pro-inflammatory conditions that lead to neurological disease? Not just as a result of weight loss, but also through the direct action of the drug?

We have limited options for treating neurodegenerative diseases like dementia, but neuroplasticity (brain remodeling) is possible.

Access yours.